Profusa (PFSA) Stock Rockets 173% After $30M Oncology Platform Deal

TLDR

• Profusa (PFSA) stock surged over 173% after announcing a letter of intent to acquire PanOmics, a next-generation sequencing diagnostics platform, from BioInsights LLC for $30 million in equity.
• The deal includes exclusive rights to the PanOmics platform, a 3% royalty on net revenue to BioInsights, and a board nomination right.
• Profusa also amended its existing financing, issuing new senior secured convertible notes worth up to $12.2 million to fund operations.
• The company is collaborating with Mayo Clinic on its Lumee oxygen platform for pancreatic procedures, which it estimates could represent a $26 million annual revenue opportunity.
• Profusa raised its 2026 revenue forecast to $1.5M–$3M, up from a prior estimate of $500K–$2M, citing stronger European distributor demand.

Profusa (PFSA) is having a wild Monday. The micro-cap biotech stock exploded more than 173% after announcing a letter of intent to acquire the PanOmics multi-omics diagnostics platform from BioInsights LLC in an all-equity deal worth approximately $30 million.

Profusa, Inc. Common Stock, PFSA

Despite the spike, context matters here. The stock is still down roughly 99.92% over the past year, and the company carries a market cap of just $870,000.

The LOI was originally signed March 31, 2026, and revised on April 3 and 4. The deal would give Profusa exclusive rights to PanOmics’ intellectual property and diagnostic platform, which focuses on next-generation sequencing (NGS) for oncology testing.

Under the terms, BioInsights will receive a 3% royalty on net revenues and the right to nominate one independent board member for stockholder consideration. BioInsights will also provide access to clinical samples for platform validation.

The transaction still needs shareholder approval, due diligence completion, and regulatory sign-off before it can close. Profusa also said it plans to raise an additional $10 million in equity financing to fund PanOmics validation and equipment.

Why the PanOmics Deal

The timing of the acquisition is tied to recent CMS reimbursement support for NGS-based oncology testing, which Profusa says creates a commercial opening. The deal is intended to diversify revenue while its core LumeeOxygen product completes clinical validation.

CEO Dr. Ben Hwang described the deal as adding $30 million of stockholder equity to the balance sheet and positioning the company in precision diagnostics. Management will also receive new equity awards equal to 12% of fully diluted shares, aligning incentives with the expanded platform.

The deal structure involves issuing both common and non-voting preferred stock, with a seven-year lock-up applied to most of BioInsights’ equity stake.

Mayo Clinic Collaboration and Revenue Outlook

Separate from the acquisition, Profusa is working with Mayo Clinic to apply its Lumee oxygen platform in pancreatic surgical monitoring. The company estimates more than 13,000 pancreatic resections are performed annually in the U.S., which it values as a $26 million annual revenue opportunity.

On the financing side, Profusa amended its securities purchase agreement on April 2, enabling it to issue up to $12.2 million in additional senior secured convertible notes. A $555,555.55 third-tranche note was issued to Ascent Partners Fund, maturing in 2027, alongside a warrant for 1,111,111 common shares at $0.50.

The company also recently scrapped a $15 million public offering in favor of a smaller raise, and terminated its Bitcoin treasury reserve strategy, liquidating all Bitcoin holdings.

Profusa has raised its full-year 2026 revenue forecast to $1.5 million–$3 million, up from the prior estimate of $500,000–$2 million, citing increased purchase orders from European distributors for the Lumee system.

The post Profusa (PFSA) Stock Rockets 173% After $30M Oncology Platform Deal appeared first on CoinCentral.